TD Asset Management Inc Sells 13,200 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Key Points

• TD Asset Management Inc reduced its stake in Janux Therapeutics by 16.7%, owning 65,636 shares after selling 13,200 shares recently.
• Institutional investors now hold 75.39% of Janux Therapeutics stock, with various funds significantly increasing their positions.
• Janux Therapeutics has reported a loss of $0.38 earnings per share, outperforming analysts' estimates, with a current consensus rating of "Buy."

TD Asset Management Inc trimmed its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 16.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,636 shares of the company's stock after selling 13,200 shares during the quarter. TD Asset Management Inc owned 0.11% of Janux Therapeutics worth $1,772,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. RA Capital Management L.P. increased its position in Janux Therapeutics by 13.1% in the fourth quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock worth $554,977,000 after buying an additional 1,200,000 shares during the last quarter. FMR LLC increased its position in Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock worth $464,189,000 after buying an additional 845,266 shares during the last quarter. Janus Henderson Group PLC increased its position in Janux Therapeutics by 41.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock worth $190,617,000 after buying an additional 1,038,996 shares during the last quarter. Paradigm Biocapital Advisors LP increased its position in Janux Therapeutics by 46.5% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock worth $188,246,000 after buying an additional 1,115,412 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in Janux Therapeutics by 47.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after buying an additional 986,750 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial initiated coverage on Janux Therapeutics in a research report on Friday, July 11th. They issued an "outperform" rating and a $65.00 target price for the company. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Janux Therapeutics presently has an average rating of "Buy" and a consensus target price of $91.89.

Janux Therapeutics Stock Up 0.3%

NASDAQ:JANX traded up $0.07 during trading hours on Friday, hitting $22.65. 499,968 shares of the company's stock traded hands, compared to its average volume of 944,167. The firm has a market cap of $1.34 billion, a P/E ratio of -16.62 and a beta of 2.86. Janux Therapeutics, Inc. has a 52 week low of $22.25 and a 52 week high of $71.71. The business's fifty day simple moving average is $24.72 and its two-hundred day simple moving average is $29.18.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07). On average, analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.